首页> 外文OA文献 >Third line Treatment in Relapsed/Refractory Hodgkin's Lymphoma and Aggressive non-Hodgkin Lymphoma after 2nd line ESHAP or GEMOX

【2h】

Third line Treatment in Relapsed/Refractory Hodgkin's Lymphoma and Aggressive non-Hodgkin Lymphoma after 2nd line ESHAP or GEMOX

机译：第三线治疗在第二线eShap或Gemox后复发/难治性Hodgkin的淋巴瘤和侵略性非霍奇金淋巴瘤

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Hamdy Zawam; Wael Edesa; Sherif Alrefai; Ahmed Abd-Elhafeez;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Axicabtagene ciloleucel (KTE-C19), an anti-CD19 CAR T therapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin’s lymphoma [J] . Michael D Jain, Christina A Bachmeier, Vania H Phuoc, Therapeutics and Clinical Risk Management . 2018,第2期

机译：Axicabtagene ciloleucel（KTE-C19），一种抗CD19 CAR T疗法，用于治疗复发/难治性侵袭性B细胞非霍奇金淋巴瘤
2. Efficacy and Toxicity of JCAR014 in Combination with Durvalumab for the Treatment of Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma [J] . Hirayama Alexandre V., Gauthier Jordan, Hay Kevin A., Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：JCAR014与Durvalumab联合治疗复发/难治性侵袭性B细胞非霍奇金淋巴瘤患者的疗效和毒性
3. Pixantrone for the treatment of adult patients with relapsed or refractory aggressive non-Hodgkin B-cell lymphomas [J] . Stefano Volpetti, Francesco Zaja, Renato Fanin OncoTargets and therapy . 2014,第3期

机译：匹克酮治疗成人复发或难治性侵袭性非霍奇金B细胞淋巴瘤
4. Development of Single Domain Antibodies for Diagnosis and Treatment of Naturally Occurring Canine Lymphoma: An Animal Model for Human Non-Hodgkin Lymphoma [C] . Joana Dias, Solange Gil, Belmira Carrapico, PEGS . 2015

机译：天然犬淋巴瘤诊断和治疗单结构域抗体的发展：人非霍奇金淋巴瘤的动物模型
5. Targeting the translational machinery as a novel treatment strategy for non-Hodgkin lymphoma. [D] . Hagner, Patrick R. 2010

机译：针对非霍奇金淋巴瘤的新型治疗策略，以翻译机制为目标。
6. Axicabtagene ciloleucel (KTE-C19) an anti-CD19 CAR T therapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin’s lymphoma [O] . Michael D Jain, Christina A Bachmeier, Vania H Phuoc, 2018

机译：Axicabtagene ciloleucel（KTE-C19）一种抗CD19 CAR T疗法用于治疗复发/难治性侵袭性B细胞非霍奇金淋巴瘤
7. IEV versus ESHAP for Treatment of the Patients with Relapsed/Refractory Hodgkin and Non-Hodgkin's Lymphoma in Iran: A Cost-Effectiveness Analysis [O] . Mostafa Habibian, Mehdi dehghani 2016

机译：IEV与eShap用于治疗伊朗复发/难治性Hodgkin和非霍奇金淋巴瘤的患者：成本效益分析

Third line Treatment in Relapsed/Refractory Hodgkin's Lymphoma and Aggressive non-Hodgkin Lymphoma after 2nd line ESHAP or GEMOX

著录项

相似文献

相关主题

期刊订阅